Open-label, Randomized, 3-period, 3-treatment Crossover, Bioequivalence Study Comparing Dasatinib (BMS-354825) Liquid Formulation and the Dispersed Tablet Formulation Relative to the Reference Tablet Formulation in Health Subjects.

Trial Profile

Open-label, Randomized, 3-period, 3-treatment Crossover, Bioequivalence Study Comparing Dasatinib (BMS-354825) Liquid Formulation and the Dispersed Tablet Formulation Relative to the Reference Tablet Formulation in Health Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2013

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Glioblastoma; Leukaemia; Malignant melanoma; Mesothelioma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Scleroderma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Aug 2011 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 03 Aug 2011 Planned end date changed from 1 Aug 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top